# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

pe Responses	s)																
1. Name and Address of Reporting Person *- Yorke Justin W				2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director10% Owner					
(Last) (First) (Middle) C/O PROCESSA PHARMACEUTICALS, INC., 7380 COCA COLA DRIVE, SUITE 106				3. Date of Earliest Transaction (Month/Day/Year) 08/05/2022							Office	r (give title belo	ow)	Other (specify	below)		
(Street) HANOVER, MD 21076				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
)	(State)	(Zip)			Ta	ble I	- Non	-Deri	ivative S	Securities	Acqu	ired, Disp	osed of, or l	Beneficially	Owned		
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	any		Code (Instr. 8)					of (D)	Beneficial Reported	ally Owned Following I Transaction(s)		Form: Direct (D)	Beneficial Ownership		
						Co	ode	V	Amoun	(A) or (D)	Price				(I) (Instr. 4)	(Instr. 4)	
Stock		03/31/2022				1	A		4,393	A	<u>(1)</u>	13,716			D		
Common Stock				532,563			I	By San Gabriel Fund, LLC, JMW Fund, LLC and the Richland Fund, LLC									
Report on a s	separate line fo	r each class of secur	ities ber	neficial	ly ov	vned o	directl	y or i	ndirectly	у.							
•							Į.	Perse	ons wh	o respoi	m are	e not requ	ired to res	spond unle	ess	1474 (9-02)	
												lly Owned					
1. Title of Derivative Security (Instr. 3)  2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Yea		3A. Deemed Execution Da any	4. te, if Transaction Code Year) (Instr. 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. T Ame Und Secu	ount of lerlying urities tr. 3 and	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	Owners Form o Derivat Securit Direct ( or India n(s) (I)	ive Ownersh (Instr. 4) (D) Pect		
				Code	V	(A)					Title	or					
	and Address of stin W  CESSA P  CESSA P  COCA  C	and Address of Reporting Persistin W  (First) (DCESSA PHARMACE 80 COCA COLA DRI (Street)  ER, MD 21076 (State)  Gecurity  2. Conversion or Exercise Price of Derivative (Month/Day/	Address of Reporting Person strin W  CESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106  (Street)  ER, MD 21076  (State)  2. Transaction Date (Month/Day/Year)  A Stock  Report on a separate line for each class of security  Table II - 1  Conversion or Exercise Price of Derivative  Derivative  Table II - 1  (Month/Day/Year)  3. Transaction Date Execution Date (Month/Day/Year)  (Month/Day/Year)	and Address of Reporting Person*    Sistin W	and Address of Reporting Person*    Strin W	and Address of Reporting Person 2 (Middle) DCESSA PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106  (Street)  4. If Amendment, ER, MD 21076  (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  1. Stock  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  3. Date of Earliest 08/05/2022  4. If Amendment, Execution Date, if any (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  3. Date of Earliest 08/05/2022  4. If Amendment, Execution Date, if any (Month/Day/Year)  5. If Amendment, Execution Date, if any (Month/Day/Year)  6. If Amendment, Execution Date, if any (Month/Day/Year)  8. If Amendment, Execution Date, if any (Month/Day/Year)  9. If Amendment, Execution Date, if any (Month/Day/Year)  9	and Address of Reporting Person Stitin W    Carrell   Ca	2. Issuer Name and Ticker of Processa Pharmaceutica  3. Date of Earliest Transaction 08/05/2022  3. Date of Earliest Transaction 08/05/2022  4. If Amendment, Date Origin  ER, MD 21076  3. Transaction Date (Month/Day/Year)  Gecurity  2. Transaction Date (Month/Day/Year)  A Stock  Report on a separate line for each class of securities beneficially owned directly any of Exercise of Date (Month/Day/Year)  2. Transaction Date (Instr. 8)  Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, opt Code (Month/Day/Year)  Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, opt Code (Month/Day/Year)  A Deemed Execution Date, if any of Code (Month/Day/Year)  A Deemed Execution Da	2. Issuer Name and Ticker or Tra Processa Pharmaceuticals, In Ocessa Pharmaceuticals, In Ocessa Pharmaceuticals, In Stock State)  (Street)	and Address of Reporting Person strin W    CFirst)	Address of Reporting Person strin W    Core   Contained   Core   Core	2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA] 3. Date of Earliest Transaction (Month/Day/Year) 80 COCA COLA DRIVE, SUITE 106  (Street)  2. Transaction Date (Month/Day/Year)  3. Transaction Date, if (Month/Day/Year)  4. If Amendment, Date Original Filed(Month/Day/Year)  4. If Amendment, Date Original Filed(Month/Day/Year)  5. Transaction Date, if (Month/Day/Year)  6. Code V Amount (A) or price of Code (Instr. 8)  8. Code V Amount (A) or price of Contained in this form are the form displays a curre  7. Table II - Derivative Securities Acquired, Disposed of, or Beneficial (Gog., puts, calls, warrants, options, convertible securities)  8. Oracle Processa Pharmaceuticals, Inc. [PCSA]  9. (Widdle)  8. (Variety Securities Acquired (A) or Disposed of, or Beneficial (Gog., puts, calls, warrants, options, convertible securities)  1. Stock  8. (Stock)  1. Stock  8. (A) (A) or Disposed of (D) (Instr. 3)  8. (A) (Instr. 3)  9. (A) (Instr. 3)  1. Transaction (Month/Day/Year)  1. Stock  9. (Code V Amount (A) or indirectly or indirectly or indirectly.  1. Stock  2. Oracle Province of Code (Instr. 8)  2. Date Excertisable (Instr. 8)  3. Transaction (A) or indirectly or indirectly.  1. Stock  1. S	Address of Reporting Person."  2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]  3. Date of Earliest Transaction (Month/Day/Year)  (Sireet)  4. If Amendment, Date Original Filed(Month/Day/Year)  (Size (Month/Day/Year)  (Month/Day/Year)  (Size (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Instr. 3, 4 and 5)  (A) or Code V Amount (O) Price (Instr. 3, and 5)  (Instr. 3) (A) or Code (Instr. 3) (I	Address of Reporting Person **  2. Issuer Name and Ticker or Trading Symbol Processas Pharmaceuticals, Inc. [PCSA]  3. Date of Farliest Transaction (Month/Day/Year)  (Size of COCA COLA DRIVE, SUITE 106  (Size of Colar Drive)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Instr. 3, 4 and 5)  (Instr. 4, 5 and 4)  (Instr. 5)  (Instr. 5)  (Instr. 6, 5 and 4)  (Instr. 6, 5 and 4)  (Instr. 7, 7 and 6, 7	Address of Reporting Person 2   2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA]   Non-Derivative Securities Acquired, Disposed of a Control of Information Control of Informatic Contr	2. Issuer Name and Ticker or Trading Symbol Processa Pharmaceuticals, Inc. [PCSA] ORGAN PHARMACEUTICALS, 80 COCA COLA DRIVE, SUITE 106  (Stree)  4. If Amendment, Date Original Filed/Manh/Buy/Vear) (Stree)  4. If Amendment, Date Original Filed/Manh/Buy/Vear) (Stree)  5. Relationship of Reporting Person (No Other (peeds)) Other (peeds) Ot	

#### **Reporting Owners**

	Relationships							
	Director	10% Owner	Officer	Other				
Reporting Owner Name / Address								

Yorke Justin W C/O PROCESSA PHARMACEUTICALS, INC 7380 COCA COLA DRIVE, SUITE 106 HANOVER, MD 21076	. X				
---	-----	--	--	--	--

## **Signatures**

/s/ Justin W. Yorke by Michael B. Kirwan, as Attorney-in-Fact	04/04/2022	
**Signature of Reporting Person	Date	

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vesting of time-based restricted shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.